Semax.

Semax is a synthetic heptapeptide derived from the adrenocorticotropic hormone (ACTH) fragment 4-10 with modifications. With the molecular formula C₃₇H₅₁N₉O₁₀ and a molecular weight of 812.9 g/mol (CA...

$32.00

Select Protocol

Lab Verified

Clinical Grade

PMID Cited

Mechanism of Action.

Published preclinical research has characterized the following molecular pathways and receptor interactions for Semax.

Neurotrophin receptor activation

BDNF/TrkB Signaling

Semax increases brain-derived neurotrophic factor expression and activates TrkB receptors in neuronal cultures.

Transcriptional regulation

Gene Expression

Research demonstrates Semax modulates expression of genes involved in neuroplasticity and neurotrophic factor production.

Evidence Based

Clinical Literature

View All Studies

Preclinical

Research review on Semax molecular characterization.

Preclinical studies have characterized the molecular properties and receptor binding profiles of Semax in standardized assay systems.

Preclinical

Semax structure-activity relationship analysis.

Structure-activity relationship studies have examined the functional domains and binding characteristics of Semax in cell-free and cell-based systems.

RESEARCH USE ONLY: This compound is intended exclusively for in vitro laboratory research. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease. Not evaluated by the FDA. Must be 21+ to purchase.

Continue Exploring